PSADT – prostate specific antigen doubling time, is a useful clinical marker for recurrence of prostate cancer post radical prostatectomy or external-beam radiation therapy. A low value general signifies a poorer prognosis.
MCP – or modified citrus pectin, are polysaccharides obtained from the peel and pulp of citrus fruits.
MCP has been clinically shown to elevate PSADT after radiation therapy to the prostate, and thus, may be a complimentary therapy.
The mechanism of action of MCP is thought to inhibit cancer cell aggregation by binding to galectin rich receptors (JNCI J Natl Cancer Inst (2002) 94 (24): 1854-1862. ) According to this article, it may have the potential to be useful for breast and colon cancer treatment and prevention of metastasis.
Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.
Prostate Oncology Specialist, Marina del Rey, California 90292, USA. Brad@prost8cancer.com
This trial investigated the tolerability and effect of modified citrus pectin (Pecta-Sol) in 13 men with prostate cancer and biochemical prostate-specific antigen (PSA) failure after localized treatment, that is, radical prostatectomy, radiation, or cryosurgery. A total of 13 men were evaluated for tolerability and 10 for efficacy. Changes in the prostate-specific antigen doubling time (PSADT) of the 10 men were the primary end point in the study. We found that the PSADT increased (P-value<0.05) in seven (70%) of 10 men after taking MCP for 12 months compared to before taking MCP. This study suggests that MCP may lengthen the PSADT in men with recurrent prostate cancer.